Innate Pharma reports preliminary Phase I clinical data for IPH 2101 (a novel, anti-KIR monoclonal antibody activating NK cells) at the ASCO meeting | Innate Pharma

Newsroom Image

Upcoming events

5th Annual European Life Science CEO Forum (Sachs forum)
06/03/2012 - 07/03/2012

Hervé Brailly, CEO, is invited to the panel discussion "French Public Markets – Breakthrough Technologies Panel".

Zurich,Switzerland

More info
Smallcap Event
12/04/2012 - 13/04/2012

Paris, France

More info

Innate Pharma reports preliminary Phase I clinical data for IPH 2101 (a novel, anti-KIR monoclonal antibody activating NK cells) at the ASCO meeting

May 29, 2009

IPH 2101 was very well tolerated at all tested doses; the pharmacodynamic endpoint was met
First Phase II trial with IPH 2101 used as a single agent in multiple myeloma to begin in 2009

Available on line:

Poster on Phase I trial in Multiple Myeloma (preliminary data)
Poster on Phase I trial in Acute Myeloid Leukemia (preliminary data)

Download Area
PR in english
CP en français